BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25603726)

  • 21. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Salzer W; Bostrom B; Messinger Y; Perissinotti AJ; Marini B
    Leuk Lymphoma; 2018 Aug; 59(8):1797-1806. PubMed ID: 29045165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged
    Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
    Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
    Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
    Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
    Wu SF; Chen AC; Peng CT; Wu KH
    Pediatr Blood Cancer; 2008 Dec; 51(6):824-5. PubMed ID: 18726919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
    J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
    Fine BM; Kaspers GJ; Ho M; Loonen AH; Boxer LM
    Cancer Res; 2005 Jan; 65(1):291-9. PubMed ID: 15665306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
    Kloos RQH; Pieters R; van den Bos C; van Eijkelenburg NKA; de Jonge R; van der Sluis IM
    Leuk Lymphoma; 2019 Dec; 60(12):3002-3010. PubMed ID: 31120351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
    Hlozkova K; Pecinova A; Alquezar-Artieda N; Pajuelo-Reguera D; Simcikova M; Hovorkova L; Rejlova K; Zaliova M; Mracek T; Kolenova A; Stary J; Trka J; Starkova J
    BMC Cancer; 2020 Jun; 20(1):526. PubMed ID: 32503472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.
    Boissel N; Sender LS
    J Adolesc Young Adult Oncol; 2015 Sep; 4(3):118-28. PubMed ID: 26421220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms of development of side effects and drug resistance to asparaginase and ways to overcome them].
    Alexandrova SS; Gladilina YA; Pokrovskaya MV; Sokolov NN; Zhdanov DD
    Biomed Khim; 2022 Apr; 68(2):104-116. PubMed ID: 35485484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
    Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
    Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
    Aydin Köker S; Oymak Y; Demirağ B; Karapinar TH; Koker A; Genç S; Erdemir G; Vergin RC
    Clin Ther; 2020 Apr; 42(4):e82-e86. PubMed ID: 32184014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical application of asparaginase activity levels following treatment with pegaspargase.
    Bleyer A; Asselin BL; Koontz SE; Hunger SP
    Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
    Panosyan EH; Seibel NL; Martin-Aragon S; Gaynon PS; Avramis IA; Sather H; Franklin J; Nachman J; Ettinger LJ; La M; Steinherz P; Cohen LJ; Siegel SE; Avramis VI;
    J Pediatr Hematol Oncol; 2004 Apr; 26(4):217-26. PubMed ID: 15087948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
    Top PC; Tissing WJ; Kuiper JW; Pieters R; van Eijck CH
    Pediatr Blood Cancer; 2005 Jan; 44(1):95-7. PubMed ID: 15368548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.